Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


APOLLO Success Clears Alnylam For Lift-Off

Executive Summary

Phase III APOLLO results finally give the beleagured firm the first late-stage success for an RNAi thereapeutic and potentially a strong lead in the rare hereditary disease. 


Related Content

Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
OliX Eyes RNAi Leadership In Asia And Beyond
Novartis Seeks EU Accelerated Review For CAR-T Therapy
Arcturus Enters Reverse-Merger With Alcobra To Push Differentiated RNA Approach
Alnylam Hopes To Resume Fitusiran Dosing Quickly, Despite Unclear Cause Of Trial Death
Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line
Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints
Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings
Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic
Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts